Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study

BACKGROUND: Pirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease. Here, we describe our almost 10 years real-life...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameli, Paolo, Refini, Rosa Metella, Bergantini, Laura, d’Alessandro, Miriana, Alonzi, Valerio, Magnoni, Carlo, Rottoli, Paola, Sestini, Piersante, Bargagli, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498677/
https://www.ncbi.nlm.nih.gov/pubmed/33102528
http://dx.doi.org/10.3389/fmolb.2020.581828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498677/
https://www.ncbi.nlm.nih.gov/pubmed/33102528
http://dx.doi.org/10.3389/fmolb.2020.581828

Ejemplares similares